High Expression of Aldo-Keto Reductase 1B10 Is an Independent Predictor of Favorable Prognosis in Patients with Hepatocellular Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Upregulation of aldo-keto reductase 1B10 (AKR1B10) through the mitogenic activator protein-1 signaling pathway might promote hepatocarcinogenesis and tumor progression. The goal of this study was to evaluate the prognostic significance of AKR1B10 protein expression in pa-tients with hepatocellular carcinoma after surgery. Methods: A tissue microarray was used to detect the expression level of AKR1B10 protein in tumors from 255 patients with hepa-tocellular carcinoma who underwent curative hepatectomy. The impact of AKR1B10 expression on the survival of pa-tients was analyzed. The median follow-up period was 119.8 months. Results: High AKR1B10 protein expression was observed in 125 of the 255 patients with hepatocellular car-cinoma (49.0%). High AKR1B10 expression was significantly associated with a lack of invasion of the major portal vein (p=0.022), a lack of intrahepatic metastasis (p=0.010), lower the American Joint Committee on Cancer T stage (p=0.016), lower the Barcelona Clinic Liver Cancer stage (p=0.006), and lower α-fetoprotein levels (p=0.020). High AKR1B10 ex-pression was also correlated with a lack of early recurrence (p=0.022). Multivariate analyses of survival revealed that intrahepatic metastases and lower albumin levels were inde-pendent predictors of both shorter recurrence-free survival and shorter disease-specific survival. High AKR1B10 expres-sion was an independent predictor of both longer recurrence-free survival (p=0.024) and longer disease-specific survival (p=0.046). Conclusions: High AKR1B10 protein expression might be useful as a marker of a favorable prognosis in pa-tients with hepatocellular carcinoma after curative hepatec-tomy.
Abstract
Background/Aims: Upregulation of aldo-keto reductase 1B10 (AKR1B10) through the mitogenic activator protein-1 signaling pathway might promote hepatocarcinogenesis and tumor progression. The goal of this study was to evaluate the prognostic significance of AKR1B10 protein expression in pa-tients with hepatocellular carcinoma after surgery. Methods: A tissue microarray was used to detect the expression level of AKR1B10 protein in tumors from 255 patients with hepa-tocellular carcinoma who underwent curative hepatectomy. The impact of AKR1B10 expression on the survival of pa-tients was analyzed. The median follow-up period was 119.8 months. Results: High AKR1B10 protein expression was observed in 125 of the 255 patients with hepatocellular car-cinoma (49.0%). High AKR1B10 expression was significantly associated with a lack of invasion of the major portal vein (p=0.022), a lack of intrahepatic metastasis (p=0.010), lower the American Joint Committee on Cancer T stage (p=0.016), lower the Barcelona Clinic Liver Cancer stage (p=0.006), and lower α-fetoprotein levels (p=0.020). High AKR1B10 ex-pression was also correlated with a lack of early recurrence (p=0.022). Multivariate analyses of survival revealed that intrahepatic metastases and lower albumin levels were inde-pendent predictors of both shorter recurrence-free survival and shorter disease-specific survival. High AKR1B10 expres-sion was an independent predictor of both longer recurrence-free survival (p=0.024) and longer disease-specific survival (p=0.046). Conclusions: High AKR1B10 protein expression might be useful as a marker of a favorable prognosis in pa-tients with hepatocellular carcinoma after curative hepatec-tomy.
참고문헌 (27)
- Poon RT, "Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge", Hepatology, 54, pp.757~759 (2011)
- Llovet JM, "Resection and liver transplantation for hepatocellular carcinoma", Semin Liver Dis, 25, pp.181~200 (2005)
- Inagaki Y, "Novel aminopeptidase N (APN", CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis, 2010, pp.4, 56~60
- Song P, "The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation", Biosci Trends, 4, pp.283~287 (2010)
- Lee KW, "Overexpression of aldose reductase in liver cancers may contribute to drug resistance", Anticancer Drugs, 12, pp.129~132 (2001)
- Barski OA, "The aldo-keto reductase superfamily and its role in drug metabolism and detoxification", Drug Metab Rev, 40, pp.553~624 (2008)
- Cao D, "Identification and characterization of a novel human aldose reductase-like gene", J Biol Chem, 273, pp.11429~11435 (1998)
- Scuric Z, "New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma", Hepatology, 27, pp.943~950 (1998)
- Fukumoto S, "Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers’ non-small cell lung carcinomas", Clin Cancer Res, 11, pp.1776~1785 (2005)
- Loeffler-Ragg J, "Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib", Mol Cancer Ther, 8, pp.1995~2006 (2009)
- Yan R, "Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention.", Int J Cancer, 121, pp.2301~2306 (2007)
- Satow R, "Combined functional genome survey of therapeutic targets for hepatocellular carcinoma", Clin Cancer Res, 16, pp.2518~2528 (2010)
- Liu Z, "Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells", Biochem J, 442, pp.273~282 (2012)
- Heringlake S, "Identification and expression analysis of the aldoketoreductase1-B10 gene in primary malignant liver tumours", J Hepatol, 52, pp.220~227 (2010)
- Edmondson HA, "Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies", Cancer, 7, pp.462~503 (1954)
- Liver Cancer Study Group of Japan, "General rules for the clinical and pathological study of primary liver cancer" (2003), Kanehara
- Edge SB, "AJCC cancer staging manual" (2010), Springer
- Llovet JM, "Prognosis of hepatocellular carcinoma:the BCLC staging classification", Semin Liver Dis, 19, pp.329~338 (1999)
- Imamura H, "Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy", J Hepatol, 38, pp.200~207 (2003)
- Shimada M, "Characteristics of multicentric hepatocellular carcinomas: comparison with intrahepatic metastasis", World J Surg, 25, pp.991~995 (2001)
- Hoshida Y, "Gene expression in fixed tissues and outcome in hepatocellular carcinoma", N Engl J Med, 359, pp.1995~2004 (2008)
- 안수민, "Metadherin Is a Prognostic Predictor of Hepatocellular Carcinoma after Curative Hepatectomy", Gut and Liver, 7(2), pp.206~212 (2013), 거트앤리버 발행위원회
- Sato S, "Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma", Liver Int, 32, pp.1382~1390 (2012)
- Wang C, "Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls", J Biol Chem, 284, pp.26742~26748 (2009)
- Yahagi N, "Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma", Eur J Cancer, 41, pp.1316~1322 (2005)
- Schmitz KJ, "AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases", Liver Int, 31, pp.810~816 (2011)
- Liu Z, "Structure and promoter characterization of aldo-keto reductase family 1 B10 gene", Gene, 437, pp.39~44 (2009)